Entering text into the input field will update the search result below

Eisai opts in to co-develop/co-promote Biogen's AD candidate aducanumab

Oct. 23, 2017 10:11 AM ETBiogen Inc. (BIIB) StockBy: Douglas W. House, SA News Editor
  • Biogen (NASDAQ:BIIB -2.1%) and collaboration partner Eisai (OTCPK:ESALY) expand their existing agreement to jointly develop and commercialize treatments for Alzheimer's disease (AD).
  • Eisai has exercised its option to co-develop and co-promote aducanumab. Biogen will receive 55% of the potential profits in the U.S. and 68.5% of the potential profits in Europe. Eisai will receive 80% of the potential profits in Japan and Asia, exclusive of China and South Korea. The companies will equally shares the potential profits in the rest of the world (ROW).
  • Biogen will book sales in the U.S., Europe and ROW while Eisai will book sales in Japan and Asia (ex. China and South Korea).
  • Biogen will continue to lead Phase 3 development of aducanumab and will be responsible for all development costs until April 2018. Eisai will reimburse Biogen for 15% of its development expenses from April 2018 through the end of the year, increasing to 45% thereafter.
  • No upfront payments are associated with Eisai's decision. Milestone payments under the original deal for aducanumab and BAN2401 have been eliminated.
  • The companies will co-promote Biogen's AVONEX (interferon beta-1a), TECFIDERA (dimethyl fumarate) and TYSABRI (natalizumab) in Japan to accounts not currently serviced by Biogen.

Recommended For You

More Trending News

About BIIB Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
BIIB--
Biogen Inc.